Skip to content

U.S. Gold Corp. USAU Warrants and Rights Outstanding

Warrants and Rights Outstanding at other companies

Nuvation Bio logo
Nuvation BioNUVB
5.8M0.0%
Microbot Medical logo
Microbot MedicalMBOT
16.3M
KEE
Keel Infrastructure Corp. Common StockKEEL
2.2M
Unusual Machines logo
Unusual MachinesUMAC
0-100%
The Marygold Companies logo
The Marygold CompaniesMGLD
82.5K
KRAKacquisition
 logo
KRAKacquisition KRAQ
0

Other financials

Income statement

See full
Operating income-$5.3M-5.0%
Net income-$5.3M+16.9%
EPS (diluted)-$0.35+35.2%

Balance sheet

See full
Cash & equivalents$36.1M+295%
Total debt$68.6K+39.4%
Total equity$52.6M+201%
Total assets$54.8M+111%

Cash flow

See full
Operating cash flow-$5.0M-59.9%
CapEx$804.8K+52,175%
Free cash flow-$5.8M

Valuation

See full
Market cap$252.96M+51.0%
Enterprise value$216.94M+37.2%
P/S14.5×

Profitability

See full
Gross margin-10.2%
Operating margin-23.8%
Net margin-23.8%
FCF margin-78.3%

Returns & leverage

See full
Return on equity-56%-15.8pp
Debt / equity0.0×
Current ratio26.6×+14.1×

Where this comes from

Reported directly by U.S. Gold Corp. in its filing.

Tagged under the XBRL concept us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights.

The official record: U.S. Gold Corp.’s 10-Q, filed March 16, 2026, on SEC EDGAR. View the filing →

Ask your AI about U.S. Gold Corp.'s warrants and rights outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is U.S. Gold Corp.'s warrants and rights outstanding?
U.S. Gold Corp. (USAU) reported warrants and rights outstanding of 625K in Q2 2025.
What is the long-term trend for U.S. Gold Corp.'s warrants and rights outstanding?
Over 3 years (2022 to 2025), U.S. Gold Corp.'s warrants and rights outstanding has grown at a 11.7% compound annual growth rate (CAGR), from 625K to 870K.
What does warrants and rights outstanding mean?
The total number of warrants and rights currently in circulation that grant holders the option to purchase company stock at a specified price. Monitoring this metric is essential for assessing the potential impact of future equity issuance on existing shareholders.